Amyloid β peptide (Aβ42) activates PLC-δ1 promoter through the NF-κB binding site
Biochemical and Biophysical Research Communications, ISSN: 0006-291X, Vol: 310, Issue: 3, Page: 904-909
2003
- 13Citations
- 14Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations13
- Citation Indexes12
- 12
- CrossRef10
- Patent Family Citations1
- Patent Families1
- Captures14
- Readers14
- Mentions1
- References1
- Wikipedia1
Article Description
The abnormal deposition of amyloid β peptide (Aβ) is a hallmark of Alzheimer’s disease (AD). Phospholipase C-δ1 (PLC-δ1) is also known to abnormally accumulate in the brains of AD patients, but no report has addressed the relationship between these two events. This study investigated the effect of Aβ42 on the PLC-δ1 expression in human neuroblastoma cell lines. The PLC-δ1 mRNA level was increased by treatment with Aβ42 in a RT-PCR analysis. In the reporter assay, Aβ42 was found to activate the PLC-δ1 promoter activity in a dose-dependent manner. A novel NF-κB binding site in the PLC-δ1 promoter appeared to be responsible for the Aβ42 activity. First, the dominant negative forms of the NF-κB activating molecules, dominant negative TGF-β activated kinase 1 (dnTAK1) and dnNIK (dominant negative NF-κB-inducing kinase), abolished the Aβ42 activity in the reporter assay. Second, the Aβ42 augmented a factor binding on the NF-κB site in the electrophoretic mobility shift assay (EMSA), which was abolished by a molar excess of the unlabeled consensus NF-κB oligonucleotide. These results suggest that the PLC-δ1 promoter is under the control of NF-κB, which mediates the expression of PLC-δ due to the Aβ42 treatment.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0006291X03018989; http://dx.doi.org/10.1016/j.bbrc.2003.09.100; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0141645325&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/14550290; https://linkinghub.elsevier.com/retrieve/pii/S0006291X03018989; https://dx.doi.org/10.1016/j.bbrc.2003.09.100
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know